Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient

Rev Esp Enferm Dig. 2021 Oct;113(10):733-734. doi: 10.17235/reed.2021.7977/2021.

Abstract

Pyoderma gangrenosum (PG) is a difficult-to-manage ulcero-necrotizing dermatosis associated with inflammatory bowel disease (IBD). In this article, we report a refractory PG in a patient with severe ulcerative colitis (UC) that responded to tofacitinib 10 mg/12 h.

Publication types

  • Letter

MeSH terms

  • Colitis, Ulcerative* / complications
  • Colitis, Ulcerative* / drug therapy
  • Humans
  • Inflammatory Bowel Diseases*
  • Piperidines
  • Pyoderma Gangrenosum* / drug therapy
  • Pyoderma Gangrenosum* / etiology
  • Pyrimidines

Substances

  • Piperidines
  • Pyrimidines
  • tofacitinib